Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mauriac

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 28, 1998
[Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate]P Richaud, N Salem, R Gaston, et al.
American Journal of Clinical Oncology|January 1, 1988
Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancerL Mauriac, P Coste, P Richaud, et al.
Annales D'Endocrinologie|January 1, 1979
[Leydig cell tumor of the ovary (biologic (in vivo and in vitro) and ultrastructural study) (author's transl)]P Roger, L Mauriac, A M Kern, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 28, 1998
[Treatment of A2-B2 prostatic cancer: results of a hormonoradiotherapy combination in the PSA era]N Salem, P Richaud, R Gaston, et al.
Cancer Treatment Reports|June 1, 1984
Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramideM David, M Durand, J Chauvergne, et al.
Bulletin Du Cancer|January 1, 1982
[High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients]N B Bui, G Marit, H Albin, et al.
Cancer Treatment Reports|June 1, 1985
Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancerJ Robert, P Vrignaud, T Nguyen-Ngoc, et al.
British Journal of Cancer|March 1, 1996
Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 casesI Soubeyran, N Quénel, L Mauriac, et al.
Breast Cancer Research and Treatment|January 5, 2002
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, T Cufer, et al.
Annales D'Endocrinologie|November 1, 1980
[The utilization of small repeated doses of iodine 131 in the treatment of Graves' disease. Results (author's transl)]J L Latapie, G Lefort, M Commenges, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 28, 1998
[Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate]P Richaud, N Salem, R Gaston, et al.
American Journal of Clinical Oncology|January 1, 1988
Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancerL Mauriac, P Coste, P Richaud, et al.
Annales D'Endocrinologie|January 1, 1979
[Leydig cell tumor of the ovary (biologic (in vivo and in vitro) and ultrastructural study) (author's transl)]P Roger, L Mauriac, A M Kern, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 28, 1998
[Treatment of A2-B2 prostatic cancer: results of a hormonoradiotherapy combination in the PSA era]N Salem, P Richaud, R Gaston, et al.
Cancer Treatment Reports|June 1, 1984
Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramideM David, M Durand, J Chauvergne, et al.
Bulletin Du Cancer|January 1, 1982
[High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients]N B Bui, G Marit, H Albin, et al.
Cancer Treatment Reports|June 1, 1985
Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancerJ Robert, P Vrignaud, T Nguyen-Ngoc, et al.
British Journal of Cancer|March 1, 1996
Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 casesI Soubeyran, N Quénel, L Mauriac, et al.
Breast Cancer Research and Treatment|January 5, 2002
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, T Cufer, et al.
Annales D'Endocrinologie|November 1, 1980
[The utilization of small repeated doses of iodine 131 in the treatment of Graves' disease. Results (author's transl)]J L Latapie, G Lefort, M Commenges, et al.
Pageof 9